Trial Profile
Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastrozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2011
Price :
$35
*
At a glance
- Drugs Toremifene (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 07 Jul 2011 Status changed from not yet recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 11 Jan 2008 New trial record.